Advanced Medical Solutions Group plc

("AMS" or the "Group")

Annual Report, Notice of Annual General Meeting and Board Change

Winsford, UK - 29 April 2022: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that the Annual Report and Accounts for the year ended 31 December 2021 and Notice of Annual General Meeting were posted to shareholders today and are available on the Investor Relations section of the Group's website.

Annual General Meeting

The Board continues to monitor the COVID-19 pandemic and our priority at this time remains the health, safety and wellbeing of all of our stakeholders. We are delighted that, at the time of issuing this Notice, we will be able to hold the AGM with no COVID-19 restrictions. However, the Board recognises that the COVID-19 pandemic is an evolving situation and that it may be necessary to modify our AGM arrangements. The arrangements are therefore subject to change, including at short notice, if circumstances and/or public health guidance changes.

The Board therefore recommends that you monitor the Company's announcements for any updates and register to receive our RNS alerts at www.admedsol.com/ investor-relations/alert-service.

The Notice of Annual General Meeting and proxy forms were posted to shareholders today and are available on the Group's website at www.admedsol.com/investor-relations. The AGM will be convened with the minimum necessary quorum of two shareholders. The outcome of the resolutions will as usual be determined by shareholder vote based on the proxy votes received.

Shareholders are strongly encouraged to vote by proxy on the resolutions contained in the AGM Notice and to appoint the "Chairman of the Meeting" as their proxy, providing instructions on how the Chair should vote on the proposed resolutions. This will ensure that your votes will be counted if you (or any other proxy who you might otherwise appoint) choose not to attend the AGM in person.

To ensure votes are counted at the AGM, completed proxy forms should be returned to: Link Group, PXS, 10th Floor, Central Square, 29 Wellington Street, Leeds, LS1 4DL and must be received by     11:00 am on 6 June 2022 in order to be valid. This is particularly important given potential delays due to the continued impact of COVID-19, which could potentially cause delays to the collection and delivery of postal services. Any shareholder who wishes to attend the AGM in person is asked to register their intention to do so as soon as practicable.

The results of the AGM will be announced to the London Stock Exchange and placed on the Group's website, in the usual way, as soon as practicable after the conclusion of the AGM.

Non-Executive Board Refreshment

As reported previously, in accordance with the 2018 UK Corporate Governance Code the Group is implementing a plan to refresh the Non-Executive members of its Board, which began in 2020 and is expected to complete in 2023.

Having appointed Grahame Cook and Douglas Le Fort as Non-Executive Directors in 2021, Penny Freer is due to retire from the Board at the upcoming AGM. It is expected that Douglas Le Fort will become Chair of the Remuneration Committee, having worked closely with Penny since he joined the Remuneration Committee in 2021. The Board would like to thank Penny for her significant contribution to the success of AMS over the last twelve years.

- End -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand^®, RESORBA^®, LiquiBandFix8^® and Seal-G^®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal^® brand as well as under white label. Since 2019, the Group has made three acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com. 

.